Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 7,720 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) CMO Joakim Wijkstrom sold 7,720 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.23, for a total value of $48,095.60. Following the completion of the transaction, the chief marketing officer now directly owns 121,653 shares in the company, valued at approximately $757,898.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock opened at $6.33 on Tuesday. Vanda Pharmaceuticals Inc. has a 52-week low of $6.18 and a 52-week high of $12.34. The firm has a market capitalization of $359.42 million, a P/E ratio of 52.75 and a beta of 0.72. The stock has a 50 day moving average price of $7.25 and a 200 day moving average price of $9.01.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Capital Advisors Ltd. LLC bought a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth $37,000. Gladius Capital Management LP bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth $45,000. PNC Financial Services Group Inc. raised its position in shares of Vanda Pharmaceuticals by 46.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 2,904 shares in the last quarter. Wedge Capital Management L L P NC bought a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth $81,000. Finally, Quantbot Technologies LP bought a new position in shares of Vanda Pharmaceuticals in the 3rd quarter worth $90,000. 97.22% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

(Get Rating)

Vanda Pharmaceuticals, Inc engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.